PepGen Inc. (PEPG) Investor Relations Documents

PepGen Inc. (PEPG) investor relations documents from the company's IR site: 1 presentation, 8 press releases; latest deck 2026-08-05. Read in-app with summaries. First-party data.

PepGen – Corporate Deck – August 2026: PepGen is developing PGN-EDODM1 for Myotonic Dystrophy Type 1, utilizing its EDO platform to achieve superior nuclear delivery of oligonucleotide therapeutics.

Investor relations documents — source: company IR site

Published	Type	Document
2026-08-06	Press release	PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
2026-08-06	Press release	PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
2026-08-05	Presentation	PepGen – Corporate Deck – August 2026
2026-05-21	Press release	PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from t
2026-05-12	Press release	PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
2026-03-30	Press release	PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrati
2026-03-04	Press release	PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights
2026-03-04	Press release	PepGen Announces Regulatory Updates on FREEDOM2
2026-03-03	Press release	PepGen to Participate in the Leerink Global Healthcare Conference

PEPG overview · PEPG earnings · PEPG financials · PEPG KPIs · PEPG ownership · PEPG peers · PEPG filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.